Resources for Food and Drug Administration (FDA)

FDA approves drug for breast cancer

www.boston.com

Eli Lilly & Co., the maker of the osteoporosis medicine Evista, won approval to use the drug to reduce risks of invasive breast cancer in certain women.
Article Tools

* PRINTER FRIENDLYPrinter friendly
* E-MAILE-mail to a friend
* RSS FEEDSBusiness RSS feed
* RSS FEEDSAvailable RSS feeds
* MOST E-MAILEDMost e-mailed
* REPRINTS & LICENSINGReprints & Licensing
* Share on DiggShare on Digg
* Share on Facebook
* Tag with Del.icio.us Save this article
* powered by Del.icio.us

More:

* Business section |
* Latest business news |
* Globe front page |
* Boston.com

* Sign up for: Globe Headlines e-mail |
* Breaking News Alerts

The Food and Drug Administration cleared the expanded marketing for postmenopausal women who have osteoporosis or are predisposed to developing the cancer, Lilly said yesterday in a statement. Tamoxifen, a generic drug, was previously the only treatment approved to prevent breast cancer.

The approval will help Evista stand out in the increasingly competitive market for drugs to prevent and treat osteoporosis, a condition in which bones become weak or brittle, analysts said. An FDA advisory panel recommended approval in July after company studies suggested that Evista may work as well as tamoxifen, with fewer dangerous side effects.

View the Resource

Share or bookmarklet this web page at: